AIDS Therapies

Ritonavir Doesn't Help Saquinavir Penetrate Sanctuary Sites

Published in AIDS Weekly, May 21st, 2001

by Michael Greer, senior medical writer - Combining ritonavir with saquinavir does not give the HIV drugs access to areas blocked by P-glycoprotein (P-gp), researchers in the Netherlands say.

"The low oral bioavailability of the HIV protease inhibitor (HPI) saquinavir is dramatically increased by co-administration of the HPI ritonavir," M.T. Huisman and colleagues explained in the journal Molecular Pharmacology. "P-gp is known to limit the ... brain, testis, and fetal penetration of its substrates, so effective inhibition of P-gp by ritonavir in vivo might open up pharmacological sanctuary sites" for the drugs.

However, Huisman and coworkers...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2001-05-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry